Literature DB >> 11312018

Immunogenicity in mice of pneumococcal glycoconjugate vaccines using pneumococcal protein carriers.

C J Lee1, T R Wang, C E Frasch.   

Abstract

Antibody response and protective immunity were evaluated in mice immunized with pneumococcal glycoconjugate vaccines using two pneumococcal protein carriers. Mice injected with type 9V polysaccharide (PS) conjugated to inactivated pneumolysin (Ply) or autolysin (Aly) produced high levels of IgG and IgM antibodies to both the PS and the protein carrier. Higher PS antibody titers to the pneumococcal PS conjugates were measured by ELISA using PS-Ply or PS-tetanus toxoid (TT) conjugate as a coating antigen compared with PS mixed with methylated human serum albumin. Type 9V PS (10 microg) inhibited most of the 9V IgM and IgG antibody binding to the 9V-TT coated plate. In contrast, absorption with 19F PS did not inhibit 9V antibody binding. The avidity index of IgG antibodies in the 9V PS-Ply serum was 55.5 +/- 0.9, compared with 47.8 +/- 1.4 for 9V PS-Aly serum. Thus, high avidity of serum antibodies in conjugate-immunized mice can provide more effective functional activity for protection against pneumococcal infection. Mice immunized with these glycoconjugates exhibited rapid bacterial clearance from blood and provided cross-protection against challenge with heterologous serotypes of virulent pneumococci. These results reveal that conjugates using pneumococcal protein carriers can induce opsonophagocytic activity to destroy homologous and heterologous pneumococci, indicating that such conjugates can confer broader protective immunity than conjugates using non-pneumococcal proteins.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11312018     DOI: 10.1016/s0264-410x(01)00033-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Mucosal immunization with recombinant fusion protein DnaJ-ΔA146Ply enhances cross-protective immunity against Streptococcus pneumoniae infection in mice via interleukin 17A.

Authors:  Yusi Liu; Hong Wang; Shuai Zhang; Lingbin Zeng; Xiuyu Xu; Kaifeng Wu; Wei Wang; Nanlin Yin; Zhixin Song; Xuemei Zhang; Yibing Yin
Journal:  Infect Immun       Date:  2014-02-03       Impact factor: 3.441

2.  A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model.

Authors:  Nelly A Kuklin; Desmond J Clark; Susan Secore; James Cook; Leslie D Cope; Tessie McNeely; Liliane Noble; Martha J Brown; Julie K Zorman; Xin Min Wang; Gregory Pancari; Hongxia Fan; Kevin Isett; Bruce Burgess; Janine Bryan; Michelle Brownlow; Hugh George; Maria Meinz; Mary E Liddell; Rosemarie Kelly; Loren Schultz; Donna Montgomery; Janet Onishi; Maria Losada; Melissa Martin; Timothy Ebert; Charles Y Tan; Timothy L Schofield; Eszter Nagy; Andreas Meineke; Joseph G Joyce; Myra B Kurtz; Michael J Caulfield; Kathrin U Jansen; William McClements; Annaliesa S Anderson
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

3.  Dendritic cells pulsed with intact Streptococcus pneumoniae elicit both protein- and polysaccharide-specific immunoglobulin isotype responses in vivo through distinct mechanisms.

Authors:  Jesus Colino; Yi Shen; Clifford M Snapper
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.